BelizeTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 1.8 (1.8–1.8)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 2 (1.4–2.6)
Prevalence  (includes HIV+TB) 0.16 (0.084–0.27) 47 (24–77)
Incidence  (includes HIV+TB) 0.13 (0.12–0.14) 37 (34–41)
Incidence (HIV+TB only) 0.024 (0.02–0.029) 6.9 (5.7–8.2)
         
Case detection, all forms (%) 55 (50–60)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.2–3.8) 100 (29–100)
MDR-TB cases among notified pulmonary
TB cases
2 (1–2) 17 (5–17)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 33   2
Pulmonary, clinically diagnosed 29    
Extrapulmonary 8   0
       
Total new and relapse 72    
Previously treated, excluding relapses 15    
Total cases notified 87    
Among 72 new and relapse cases:
5 (7%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 2 (6%) 2 (12%) 4
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment ***     1
TB/HIV 2014 Number (%)
TB patients with known HIV status 63 (72)
HIV-positive TB patients 25 (40)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 25 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 25 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (36) 121
Previously treated cases, excluding relapse, registered in 2013 (67) 3
HIV-positive TB cases, all types, registered in 2013 (12) 25
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 2.3
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) <1
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-05 Data: www.who.int/tb/data